Alpha Tau Medical has received FDA clearance to complete enrollment in its REGAIN trial targeting recurrent glioblastoma, with the agency also approving the addition of two U.S. clinical sites. The announcement, dated June 11, 2026, follows early interim results that reported 100% local disease control among evaluable patients — a clinical endpoint that, if sustained in a fully powered cohort, would represent a meaningful benchmark in a disease category with historically poor prognosis.
The REGAIN trial evaluates Alpha Tau's Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform, a locoregional delivery mechanism designed to deposit alpha-particle radiation directly into solid tumors. Unlike systemic oncology agents, the mechanism of action is physical rather than biochemical — alpha particles travel only micrometers in tissue, concentrating cytotoxic dose at the tumor site while limiting off-target exposure. The early interim read-out, though not yet peer-reviewed or published in a indexed journal, provided sufficient clinical signal for the FDA to authorize trial continuation and site expansion.
From a channel perspective, Alpha DaRT is a medical device and radiation therapy system, not a dietary supplement, finished formulation, or functional food ingredient. It carries no structure-function claim, is not governed by DSHEA, and does not require GRAS affirmation or an NDI notification. Coverage in a functional-foods context is therefore framed as adjacent science — the kind of locoregional precision-delivery innovation that increasingly informs how ingredient suppliers and nutraceutical formulators think about targeted bioavailability and site-specific efficacy, even if the regulatory and commercial pathways diverge sharply. Operators tracking the broader wellness-to-clinical continuum will note the directional interest in precision dose delivery that parallels ongoing work in liposomal encapsulation and nanoparticle carriers within the supplement space.
The recurrent glioblastoma market remains one of the most underserved oncology segments, with median overall survival measured in months under current standard of care. Expansion to additional U.S. sites accelerates enrollment velocity and may shorten the timeline to a pivotal data readout. For trade readers monitoring the intersection of clinical trial design and nutraceutical evidence standards, the REGAIN interim results underscore how rigorously defined clinical endpoints — local disease control rates, progression-free survival — contrast with the softer evidence bases that often underpin structure-function claims in the supplement industry.
Alpha Tau has not disclosed enrollment targets, trial completion timelines, or commercial partnership arrangements in connection with this clearance. Further peer-reviewed data and a full interim analysis are anticipated as enrollment progresses across the expanded site network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.